Aug 14, 2023 4:15pm EDT iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
Jun 27, 2023 8:00am EDT iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
Jun 06, 2023 8:00am EDT iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
Apr 04, 2023 4:05pm EDT iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
